Antitumor effect of the vascular-disrupting agent ZD6126 in a murine renal cell carcinoma model

International Journal of Oncology

Volumn 38, Issue 2, 2011, Pages 455-464

  Medinger, M ^a,e   Esser, N ^b   Soltau, J ^a   Lehmann, K M ^c   Konerding, M A ^c   Wolloscheck, T ^c   Ryan, A J ^d   Drevs, J ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b PROQINASE GMBH   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d ASTRAZENECA   (United Kingdom)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Angiogenesis; Corrosion cast; Murine renal cell carcinoma; Vascular disrupting agents; ZD6126

Indexed keywords

N ACETYLCOLCHINOL PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR BLOOD FLOW; TUMOR NECROSIS; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPHOSPHORUS COMPOUNDS;

EID: 78651244619     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2010.867     Document Type: Article

References (29)

1. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
2. Medinger M and Drevs J: Receptor tyrosine kinases and anticancer therapy. Curr Pharm Des 11: 1139-1149, 2005.
3. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
4. Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Muller M, Wood J, Martiny-Baron G, Unger C and Marme D: Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60: 4819-4824, 2000.
5. Drevs J, Konerding MA, Wolloscheck T, Wedge SR, Ryan AJ, Ogilvie DJ and Esser N: The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma. Angiogenesis 7: 347-354, 2004.
6. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362: 841-844, 1993.
7. Medinger M, Esser N, Zirrgiebel U, Ryan A, Jürgensmeier JM and Drevs J: Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma. Anticancer Res 29: 5065-5076, 2009.
8. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R and Bukowski RM: Target Study Group: sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134, 2007.
9. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM and Figlin RA: Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124, 2007.
10. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
11. Thorpe PE: Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10: 415-427, 2004.
12. Tozer GM, Kanthou C and Baguley BC: Disrupting tumor blood vessels. Nat Rev Cancer 5: 423-435, 2005.
13. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ and Hill SA: ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62: 7247-7253, 2002.
14. Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE and Ryan AJ: Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8: 1974-1983, 2002.
15. Siemann DW and Rojiani AM: Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 53: 164-171, 2002.
16. Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, Langmuir P, Wheeler C, Stone A, Leadbetter J, Ryan AJ, Blakey DC and Waterton JC: Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 10: 3650-3657, 2004.
17. Beerepoot LV, Radema SA, Witteveen EO, Thomas T, Wheeler C, Kempin S and Voest EE: Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 24: 1491-1498, 2006.
18. LoRusso PM, Gadgeel SM, Wozniak A, Barge AJ, Jones HK, DelProposto ZS, DeLuca PA, Evelhoch JL, Boerner SA and Wheeler C: Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs 26: 159-167, 2008.
19. Drevs J and Schneider V: The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumor agents targeting angiogenesis. J Intern Med 260: 517-529, 2006.
20. Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, Jürgensmeier JM, Puchalski TA, Young H, Saunders O and Unger C: Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25: 3045-3054, 2007.
21. Drevs J, Medinger M, Mross K, Fuxius S, Hennig J, Buechert M, Thomas A, Unger C, Chen BL, Lebwohl D and Laurent D: A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer. Anticancer Res 30: 2335-2339, 2010.
22. Murphy GP and Hrushesky WJ: A murine renal cell carcinoma. J Natl Cancer Inst 50: 1013-1025, 1973.
23. Goertz DE, Yu JL, Kerbel RS, Burns PN and Foster FS: High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Res 62: 6371-6375, 2002.
24. Carmeliet P: Angiogenesis in health and disease. Nat Med 9: 653-660, 2003.
25. Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC and Sone S: Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lungadenocarcinoma in nude mice. Cancer Res 62: 3711-3715, 2002.
26. Horsman MR and Murata R: Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 57: 1047-1055, 2003.
27. Kleespies A, Köhl G, Friedrich M, Ryan AJ, Barge A, Jauch KW and Bruns CJ: Vascular targeting in pancreatic cancer: the novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models. Neoplasia 7: 957-966, 2005.
28. Konerding MA, Fait E and Gaumann A: 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon. Br J Cancer 84: 1354-1362, 2001.
29. Konerding MA, Malkusch W, Klapthor B, et al: Evidence for characteristic vascular patterns in solid tumors: quantitative studies using corrosion casts. Br J Cancer 80: 724-732, 1999.